Valuation: Sionna Therapeutics, Inc.

Market Cap 134M 122M 113M 102M 192M 12.55B 201M 1.37B 543M 6.78B 504M 493M 21.48B P/E 2026 *
-1.16x
P/E 2027 * -1.32x
Enterprise Value 37.87M 34.5M 31.94M 28.89M 54.2M 3.54B 56.73M 386M 153M 1.91B 142M 139M 6.05B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
91.98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Sionna Therapeutics, Inc.

1 day+1.01%
1 week-11.37%
Current month-21.45%
1 month-24.19%
3 months-51.36%
6 months-91.93%
Current year-92.61%
1 week 2.89
Extreme 2.89
3.58
1 month 2.89
Extreme 2.89
4.31
Current year 2.89
Extreme 2.89
54.97
1 year 2.89
Extreme 2.89
54.97
3 years 2.89
Extreme 2.89
54.97
5 years 2.89
Extreme 2.89
54.97
10 years 2.89
Extreme 2.89
54.97
Manager TitleAgeSince
Corporate Officer/Principal - 31/07/2019
Corporate Officer/Principal - 31/07/2019
Chief Executive Officer 55 30/04/2021
Director TitleAgeSince
Director/Board Member 51 30/11/2019
Director/Board Member 44 30/11/2019
Director/Board Member 52 31/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
17/09/26 Free

General Counsel

262,545 0.5807%
17/09/26 Free

Chief Financial Officer

425,417 0.9409%
17/09/26 Free

Chief Technology Officer

411,400 0.9099%
Change 5-day change 1-year change 3-year change Capi.($)
+1.01%-11.37%-92.09% - 134M
+0.19%-2.90%+56.40%+69.15% 65.45B
-0.14%-3.20%+7.62%+90.41% 58.93B
+0.06%+0.15%+25.94%+86.73% 55.21B
-0.37%-3.12%+13.90%+114.49% 46.1B
-1.65%-6.21%+16.92%+23.86% 42.49B
+3.61%+3.86%+22.82%+46.39% 35.56B
+0.89%-7.76%+130.63%+648.55% 34.57B
+0.03%-0.93%+76.71%+57.52% 32.46B
+18.71%+21.22%-29.69%+481.34% 26.28B
Average +2.39%-4.61%+22.92%+179.83% 40B
Weighted average by Cap. +1.63%-2.70%+35.14%+149.91%

Financials

2026 *2027 *
Net sales - -
Net income -116M -106M -97.75M -88.42M -166M -10.82B -174M -1.18B -469M -5.85B -435M -426M -18.53B -108M -98.61M -91.28M -82.57M -155M -10.11B -162M -1.1B -438M -5.46B -406M -398M -17.3B
Net Debt -96.48M -87.9M -81.37M -73.6M -138M -9.01B -145M -984M -390M -4.87B -362M -354M -15.42B -233M -212M -197M -178M -334M -21.78B -349M -2.38B -943M -11.77B -875M -857M -37.28B
Projected Income Statement - Annual - Sionna Therapeutics, Inc.
Logo Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Employees
59
Date Price Change Volume
19/11/26 US$3.040 +2.36% 407,339
18/11/26 US$2.970 -3.26% 515,135
17/11/26 US$3.070 -1.60% 553,484
16/11/26 US$3.120 -6.31% 554,367
13/11/26 US$3.330 -2.92% 470,236
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Sionna Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
2.970USD
Average target price
21.00USD
Spread / Average Target
+607.07%
  1. Stock Market
  2. Stocks
  3. SION Stock